VIA Pharmaceuticals, Inc. (VIAP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VIA Pharmaceuticals, Inc. (VIAP) trades at $0.00. VIA Pharmaceuticals, Inc. is a development stage biotechnology company focused on creating small molecule drugs for cardiovascular and metabolic diseases. Market cap: $10,279, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for VIAP: VIAP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIAP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VIAP: 1/1 perspectives are bearish.
How is this calculated? →VIA Pharmaceuticals, Inc. (VIAP) Healthcare & Pipeline Overview
VIA Pharmaceuticals, Inc., a development-stage biotech firm, is focused on developing small molecule drugs targeting cardiovascular and metabolic diseases. Their pipeline includes VIA-3196 for dyslipidemia, a DGAT1 inhibitor for type 2 diabetes, and VIA-2291 for atherosclerotic plaque, positioning them in a competitive pharmaceutical landscape.
What Is the Investment Thesis for VIAP?
VIA Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of early-stage biotechnology companies. The company's value hinges on the successful development and commercialization of its drug pipeline, particularly VIA-3196, which is Phase-1 ready. Positive clinical trial results for VIA-3196 and the DGAT1 inhibitor could serve as major catalysts, driving significant stock appreciation. The agreements with Hoffman-LaRoche provide validation and potential revenue streams. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional funding. With a market cap of 10K and a negative P/E ratio, the company's valuation is speculative and dependent on future success.
Based on FMP financials and quantitative analysis
VIAP Key Highlights
- VIA-3196 is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist targeting dyslipidemia.
- DGAT1 inhibitor is in pre-clinical development for the treatment of type 2 diabetes.
- VIA-2291, a 5-Lipoxygenase inhibitor, has completed Phase 2 clinical trials for the treatment of atherosclerotic plaque.
- VIA Pharmaceuticals has research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd.
- The company has a Beta of -0.60, indicating a potential inverse correlation with market movements, but this may be unreliable given the company's OTC status and limited trading volume.
Who Are VIAP's Competitors?
VIAP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIAP's Key Strengths?
- Proprietary drug candidates targeting significant unmet needs.
- Established partnerships with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Focus on underlying causes of cardiovascular and metabolic diseases.
What Are VIAP's Weaknesses?
- Early-stage development company with limited financial resources.
- High dependence on successful clinical trial outcomes.
- Limited commercialization capabilities.
- OTC market listing indicates higher risk and lower liquidity.
What Could Drive VIAP Stock Higher?
- Initiation of Phase 2 clinical trials for VIA-3196, pending successful Phase 1 results.
- Announcement of new partnerships or licensing agreements for drug candidates.
- Continued development and advancement of the DGAT1 inhibitor program.
- Publication of positive preclinical or clinical data in peer-reviewed journals.
What Are the Key Risks for VIAP?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for VIA-3196 or other drug candidates.
- Regulatory delays or rejection of drug approvals.
- Competition from established pharmaceutical companies with greater resources.
- Need for additional funding and potential dilution of existing shareholders.
- Intellectual property challenges or patent infringement claims.
What Are the Growth Opportunities for VIAP?
- Advancement of VIA-3196: The successful completion of Phase 1 clinical trials for VIA-3196 and subsequent progression through further clinical stages represents a significant growth opportunity. Positive data demonstrating efficacy and safety in treating dyslipidemia could attract further investment and partnership opportunities. The dyslipidemia market is substantial, with a global market size estimated at billions of dollars, offering significant revenue potential for a successful therapy.
- Development of DGAT1 Inhibitor: The pre-clinical development of the DGAT1 inhibitor for type 2 diabetes presents another growth avenue. If successful, this inhibitor could address a significant unmet need in diabetes treatment, particularly in patients with co-existing dyslipidemia and weight control issues. The global type 2 diabetes market is one of the largest in the pharmaceutical industry, providing a substantial commercial opportunity.
- Partnerships and Licensing Agreements: VIA Pharmaceuticals can pursue additional partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These collaborations can provide financial resources, expertise, and access to established distribution networks, increasing the likelihood of successful market entry. The existing agreements with Hoffman-LaRoche serve as a precedent for future collaborations.
- Expansion into New Therapeutic Areas: While currently focused on cardiovascular and metabolic diseases, VIA Pharmaceuticals could expand its research and development efforts into related therapeutic areas, such as obesity or non-alcoholic steatohepatitis (NASH). These areas share similar underlying mechanisms and risk factors, creating synergies for drug development. The NASH market, in particular, is rapidly growing and represents a significant opportunity.
- Strategic Acquisitions: VIA Pharmaceuticals could consider strategic acquisitions of other biotechnology companies with complementary technologies or drug candidates. This could broaden its pipeline, diversify its risk profile, and accelerate its growth trajectory. However, given its current financial position, any acquisition would likely require external funding or a merger with another entity.
What Opportunities Does VIAP Have?
- Advancement of drug candidates through clinical trials.
- Expansion into new therapeutic areas.
- Securing additional partnerships and licensing agreements.
- Potential for breakthrough therapies with significant market potential.
What Threats Does VIAP Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Need for additional funding and potential dilution of existing shareholders.
What Are VIAP's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Specialized expertise in cardiovascular and metabolic disease drug development.
- Established partnerships with major pharmaceutical companies.
- First-mover advantage in specific therapeutic areas.
What Does VIAP Do?
Founded in 2004 and headquartered in San Francisco, VIA Pharmaceuticals, Inc. is a biotechnology company in the development stage, concentrating on creating innovative treatments for cardiovascular and metabolic diseases. The company's mission is to address the underlying causes of these conditions through a pipeline of small molecule drugs. VIA Pharmaceuticals is actively developing therapies targeting vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. Their lead drug candidate, VIA-3196, is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist designed to treat dyslipidemia, including high LDL cholesterol, high triglycerides, and elevated Lp(a). Another key program involves a Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, currently in pre-clinical development, aimed at treating type 2 diabetes with potential benefits in weight control and dyslipidemia. VIA-2291, a 5-Lipoxygenase inhibitor, has completed Phase 2 clinical trials for treating atherosclerotic plaque, a primary cause of heart attacks and strokes. VIA Pharmaceuticals has established research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonists and multiple compounds from its preclinical DGAT1 metabolic disorders program.
What Products and Services Does VIAP Offer?
- Develops small molecule drugs for cardiovascular diseases.
- Creates treatments for metabolic diseases.
- Targets vascular inflammation.
- Addresses high cholesterol and high triglycerides.
- Develops therapies for insulin sensitization/diabetes.
- Focuses on atherosclerotic plaque treatment.
How Does VIAP Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks partnerships with larger pharmaceutical companies for commercialization.
- Out-licenses or sells drug candidates to generate revenue.
What Industry Does VIAP Operate In?
VIA Pharmaceuticals operates within the competitive pharmaceutical industry, specifically targeting cardiovascular and metabolic diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical giants and other biotech firms. The market for cardiovascular and metabolic disease treatments is substantial and growing, driven by aging populations and increasing prevalence of these conditions. VIA Pharmaceuticals' success depends on its ability to develop and commercialize innovative therapies that address unmet needs in these markets.
Who Are VIAP's Key Customers?
- Large pharmaceutical companies seeking to expand their product portfolios.
- Patients suffering from cardiovascular and metabolic diseases.
- Healthcare providers prescribing treatments for these conditions.
- Research institutions involved in clinical trials.
Net buyingInsider Activity
The most recent 12 insider filings for VIA Pharmaceuticals, Inc. break down as 4 sales and 8 purchases. On net that is roughly 13.0M shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.
F-Score 1/9Financial Health
VIA Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 65%Key Financial Metrics
Return on equity for VIA Pharmaceuticals, Inc. stands at 64.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
VIA Pharmaceuticals, Inc. (VIAP) Valuation Context
Valued at 10K, VIAP is classified as a micro-cap stock.
Company Profile
VIA Pharmaceuticals, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Thomas Quertermous. VIAP has traded publicly since 2007.
VIAP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidates targeting significant unmet needs.
- Established partnerships with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Focus on underlying causes of cardiovascular and metabolic diseases.
Bear Case
- Early-stage development company with limited financial resources.
- High dependence on successful clinical trial outcomes.
- Limited commercialization capabilities.
- OTC market listing indicates higher risk and lower liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
VIAP Latest News
No recent news available for VIAP.
VIAP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIAP.
Price Targets
Wall Street price target analysis for VIAP.
VIAP MoonshotScore
What does this score mean?
The MoonshotScore rates VIAP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas Quertermous
CEO
Thomas Quertermous serves as the CEO of VIA Pharmaceuticals, Inc. His background likely includes extensive experience in the biotechnology or pharmaceutical industry, with a focus on drug development and management. Further details regarding his education, previous roles, and specific credentials are not available in the provided data.
Track Record: Given the limited information, it is difficult to assess Thomas Quertermous's specific track record at VIA Pharmaceuticals. However, as CEO, he is responsible for guiding the company's strategic direction, overseeing drug development programs, and securing partnerships and funding. The company's progress in advancing its drug pipeline, including VIA-3196 and the DGAT1 inhibitor, would be key indicators of his leadership.
VIAP OTC Market Information
The OTC Other tier, where VIA Pharmaceuticals trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure, may not meet minimum listing requirements, and are generally considered to be higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ. These companies may be defunct, shell companies, or in financial distress. Investing in OTC Other stocks requires significant due diligence due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in VIA Pharmaceuticals.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- The OTC Other tier designation indicates a higher risk of fraud or manipulation.
- VIA Pharmaceuticals may be subject to delisting or trading suspensions.
- The company's financial stability and ability to continue operations are uncertain.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's intellectual property and patent protection.
- Evaluate the potential market for the company's products or services.
- Determine the company's cash burn rate and funding needs.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC Other stocks.
- Research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd.
- Development of a pipeline of small molecule drugs targeting cardiovascular and metabolic diseases.
- VIA-3196 is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist.
- Company was founded in 2004.
Common Questions About VIAP (Healthcare)
What does VIA Pharmaceuticals, Inc. do?
VIA Pharmaceuticals, Inc. is a development-stage biotechnology company focused on creating small molecule drugs for the treatment of cardiovascular and metabolic diseases. Their pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist for dyslipidemia; a Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor in pre-clinical development for type 2 diabetes; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed Phase 2 clinical trials for atherosclerotic plaque. The company aims to address the underlying causes of these diseases through innovative therapies.
What do analysts say about VIAP stock?
Given that VIA Pharmaceuticals trades on the OTC market and has a market cap of 10K, formal analyst coverage is unlikely. The company's valuation is speculative and dependent on the successful development and commercialization of its drug pipeline. Investors should conduct their own thorough due diligence and consider the significant risks associated with investing in early-stage biotechnology companies, particularly those trading on the OTC market. The absence of analyst ratings reflects the high-risk nature of this investment.
What are the main risks for VIAP?
VIA Pharmaceuticals faces significant risks inherent to early-stage biotechnology companies. These include the risk of clinical trial failures, regulatory hurdles, and the need for substantial additional funding. Competition from larger pharmaceutical companies with greater resources poses a threat. Furthermore, as an OTC-listed company, VIA Pharmaceuticals is subject to lower liquidity, increased volatility, and a higher risk of fraud or manipulation. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for VIAP?
Evaluate VIAP on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does VIAP data refresh on this page?
VIAP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VIAP's recent stock price performance?
VIA Pharmaceuticals, Inc. (VIAP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates targeting significant unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIAP overvalued or undervalued right now?
Valuing VIA Pharmaceuticals, Inc. (VIAP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VIAP?
Before investing in VIA Pharmaceuticals, Inc. (VIAP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market stocks carry higher risk.
- AI analysis pending.